Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up

This follow‐up extension of a randomised phase II study assessed differences in long‐term outcomes between bortezomib‐thalidomide‐dexamethasone (VTD) and VTD‐cyclophosphamide (VTDC) induction therapy in multiple myeloma. Newly diagnosed patients (n = 98) were randomised 1:1 to intravenous bortezomib...

Descripción completa

Detalles Bibliográficos
Autores principales: Ludwig, Heinz, Greil, Richard, Masszi, Tamas, Spicka, Ivan, Shpilberg, Ofer, Hajek, Roman, Dmoszynska, Anna, Paiva, Bruno, Vidriales, María‐Belén, Esteves, Graca, Stoppa, Anne Marie, Robinson, Don, Chaturvedi, Shalini, Ataman, Ozlem, Enny, Christopher, Feng, Huaibao, van de Velde, Helgi, Viterbo, Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758383/
https://www.ncbi.nlm.nih.gov/pubmed/26153365
http://dx.doi.org/10.1111/bjh.13582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758383/
https://www.ncbi.nlm.nih.gov/pubmed/26153365
http://dx.doi.org/10.1111/bjh.13582

Ejemplares similares